News

Shares of ResMed (NYSE: RMD) had soared 16.2% higher as of 11:50 a.m. ET on Friday. The big jump came after the healthcare technology company reported results on Thursday evening for its fiscal 2024 third quarter, which ended March 31.

For the quarter, ResMed reported revenue of $1.2 billion, up 7% year over year, and earnings per share of $2.04, based on generally accepted accounting principles (GAAP). The company also reported non-GAAP (adjusted) earnings per share of $2.13, handily beating the consensus Wall Street estimate of $1.91.

Behind ResMed's soaring profits

The most important driver of ResMed's profit growth was strong demand for the company's medical devices and software -- particularly its sleep devices. The company also reported double-digit percentage revenue growth for its mask products and accessories. Software-as-a-service revenue rose by 8% year over year.

ResMed's improving margins also contributed to the increased profitability. The company's gross margins rose by 260 basis points on a GAAP and non-GAAP basis. Management attributed those improvements mainly to reduced freight and manufacturing costs.

Is ResMed stock a buy?

Worries that the growing use of weight-loss drugs Wegovy and Zepbound would lead to a reduction in the size of the market for ResMed's sleep devices appear to have been overblown. ResMed CEO Michael Farrel said on the quarterlyearnings callthat patients taking these GLP-1 agonists are actually 10.5% more likely to start positive airway pressure (PAP) therapy than those who aren't taking those drugs.

After ResMed's great fiscal Q3 results, is its stock a buy? I think is an OK pick. However, in my view, many other stocks offer even better growth prospects.

Should you invest $1,000 in ResMed right now?

Before you buy stock in ResMed, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ResMed wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

*Stock Advisor returns as of April 22, 2024

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ResMed. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.